

Cancer du sein métastatique

Dr Anne-Claire Hardy-Bessard

Centre Armoricain d'Oncologie


CARIO HPCA, Plérin





ARCAGY - GINECO

DOLAF PHASE 2


- Metastatic or locally advanced ER-positive, HER2-
- Criteria that predict sensitivity to olaparib
 - germline or somatic BRCA mutation
 - deleterious alteration of other genes involved in homologous recombination repair (HRR)
 - mismatch repair genes, or a high mutation load
- Primary : PFSrate at 24 weeks
- PI UCBG Séverine GIU, PI GINECO Philippe FOLLANA



DOLAF PHASE 2



DOLAF




Number of screened patients 170

Number of included patients 53

France

Number of declared sites 32
Number of opened sites 25
Number of active sites 21




Spain

Number of declared sites 15
Number of opened sites 10
Number of active sites 0

Belgium


Number of declared sites 5
Number of opened sites 0
Number of active sites 0

DOLAF



AMBRE

- visceral involvement of one site with more than 3 lesions.
- visceral involvement of at least 2 sites.
- symptomatic ascites or pleural effusion, defined as the need for weekly puncture with visceral measurable metastases.
- visceral involvement and LDH > N.





PI UCBG V Diéras, PI GINECO G Freyer

Autorisation ANSM 30/01/2020
Avis du CPP 10/01/2020

Première mise en place 09/03/2020
Nombre de sites activés 25/45
Première inclusion 11/06/2020


Nombre de patientes incluses: 14

Nombre de patientes randomisées: 13/378



AMBRE

N°du Site	Sites	Ville	Nom du PI	Date d'activation du site	Date de première inclusion	Date de dernière inclusion	Nombre de patientes incluses	Nombre de patientes randomisée	Nombre de screenfailure (incluses non randomisées)
01	Centre Eugène Marquis	RENNES	Dr DIERAS	18/05/2020	14/09/2020	04/11/2020	3	3	
02	Hospices Civils de Lyon - Centre Hospitalier Lyon Sud	PIERRE BENITE	Dr PERON	11/06/2020	11/06/2020	11/06/2020	1	0	1
03	Institut Sainte Catherine	AVIGNON	Dr GRENIER	29/06/2020	27/01/2021	27/01/2021	1	1	
04	Centre Francois Baclesse	CAEN	Dr LEVY	05/08/2020	10/09/2020	10/09/2020	1	1	
06	CHU Limoges	Limoges	Dr LAVAU DENES	14/09/2020	30/09/2020	30/09/2020	1	1	
07	Clinique mutualiste de l'Estuaire	SAINT-NAZAIRE	Dr DELECROIX	23/09/2020					
08	Centre Henri Becquerel	ROUEN	Dr CLATOT	03/08/2020					
09	Centre hospitalier FLEYRIAT	BOURG EN BRESSE	Dr ORFEUVRE	29/06/2020	01/09/2020	01/09/2020	1	1	
10	Hopitaux du leman	THONON LES BAINS	Dr DEL PIANO	18/12/2020					
11	Centre Hospitalier de la Côte Basque	BAYONNE	Dr MINNE	29/06/2020					
12	Institut de Cancérologie Lucien Neuwirth	SAINT-PRIEST-EN-JAREZ	Dr JACQUIN	17/09/2020	09/12/2020	08/01/2021	3	3	
15	Hôpital Privé Paul D' Egine	CHAMPIGNY SUR MARNE	Dr DEMIL	31/07/2020					
17	CH Métropole Savoie	CHAMBERY	Dr MARQUES	09/10/2020					
18	Clinique des Cèdres	CORNEBARRIEU	Dr CARPUIC	18/02/2021					
20	GHBS Lorient	LORIENT	Dr LAMY	01/07/2020					
23	Centre Jean Perrin	CLERMONT FERRAND	Pr DURANDO	27/08/2020					
24	Institut Curie_site Paris	PARIS	Pr BIDARD	26/02/2021					
25	Institut Curie_site St-Cloud	SAINT-CLOUD	Pr BIDARD	25/02/2021					
28	Institut Jean Godinot	REIMS CEDEX	Dr JOUANNAUD	09/07/2020	21/12/2020	22/12/2020	2	2	
29	Institut de Cancérologie de Lorraine	VANDOEUVRE LES NANCY	Dr UWER	04/12/2020	08/01/2021	08/01/2021	1	1	
30	Hôpital privé Jean Mermoz	LYON	Dr DERBEL	12/11/2020					
33	Centre Léon Berrard	LYON	Dr BACHELOT	12/02/2021					
37	Centre Hospitalier de Perpignan	PERPIGNAN	Dr BAREL	26/10/2020					
38	Hôpital Privé des Côtes d'Armor	PLERIN	Dr HARDY-BESSARD	27/08/2020					
45	Centre Hospitalier de Cahors	CAHORS	Dr LEVASSEUR	25/02/2021					
							Total	14	13
								1	




INTTERCEPT

HER2CLIMB Randomized, Double-blind, Pivotal Trial

Key Eligibility Criteria

- HER2+ metastatic breast cancer
- Prior treatment with trastuzumab, pertuzumab, and T-DM1
- ECOG performance status 0 or 1
- Brain MRI at baseline

*Stratification factors: presence of brain metastases (yes/no), ECOG status (0 or 1), and region (US or Canada or rest of world)



HER2CLIMB : METASTASES CEREBRALES

All Patients with Brain Metastases N=291


Active Brain Metastases N=174

Treated Progressing N=108 Previously treated but progression of existing lesions, new lesions or untreated lesions at baseline

Untreated N=66


Treated Stable Brain Metastases[†] N=117 Previously treated and no evidence of progression at baseline

[†]Includes patients requiring immediate local therapy before enrollment. These patients were not considered evaluable for intracranial response.



Progression-Free Survival* in Patients with Brain Metastases

Alpha-controlled secondary endpoint in the HER2CLIMB trial



*PFS, defined as time from randomization to documented disease progression (assessed by blinded independent central review) or death from any cause. Analysis does not include patients with dural lesions only.

PRESENTED AT: 2020 ASCO ANNUAL MEETING


#ASCO20
Slides are the property of the author,
permission required for reuse.

	Events N=291	HR (95% CI)	P Value
TUC+Tras+Cape	106/198	0.48 (0.34, 0.69)	<0.00001
Pbo+Tras+Cape	51/93		

Prespecified efficacy boundary for PFS-brain metastases ($P=0.0080$) was met at the first interim analysis.
Data cut off: Sep 4, 2019


Murthy RK, et al. *N Engl J Med* 2020;382:597-609.

CNS-PFS Benefit in Patients with Brain Metastases



by: Nancy Lin, nlin@partners.org

OS Benefit in Patients with Brain Metastases



HR: hazard ratio computed from Cox proportional hazards model using stratification factors (ECOG performance status: 0/1, and Region of world: North America/Rest of World) at randomization. All P values are nominal.

PRESENTED AT: 2020 ASCO ANNUAL MEETING

#ASCO20
Slides are the property of the author,
permission required for reuse.

PRESENTED BY: Nancy Lin, nlin@partners.org

INTTERCEPT

- Cancer du sein HER+ en progression cérébrale isolée sous Trastu + Pertu (+/- taxane), pas de maladie lepto-méningée
- Traitement local des métas cérébrales terminé depuis moins de 12 semaines
- Pas de progression extra-cérébrale au moment de l'inclusion
- Adjonction du TUCATINIB
- Objectif principal : taux de PFS à 6 mois



PI UCBG Thomas Bachelot, PI GINECO AC Hardy-Bessard

INTTERCEPT

Duration

INCLUSION PERIOD: 24 months

TRIAL TREATMENT PERIOD: Until disease progression or unacceptable toxicity or patient's decision.

FOLLOW-UP: 18 months from enrollment

DURATION UNTIL PRIMARY ENDPOINT EVALUATION: 30 months

OVERALL TRIAL DURATION (INCLUDING FOLLOW-UP): 42 months

Number of centers & number of patients expected

- 30 centers
- 65 patients

